The Efferent Board of Advisors is comprised of highly respected healthcare professionals and business experts that bring a wealth of knowledge across multiple disciplines as well as invaluable experience and scientific direction.
Mr. McCarthy is an advisor on technology to Efferent Labs. Ed currently serves as Vice President of Operations at Vnomics. Prior to this position he was the Senior Program Manager at the Center for Integrated Manufacturing Studies at Rochester Institute of Technology (RIT). At RIT he was responsible for developing and directing strategic initiatives for a research partnership with the Department of Defense. He was also an RIT Reliability Center Maintenance facilitator with experience in both military and industrial applications.
Michael Weintraub, MD
Dr. Weintraub works with clients designing clinical trials in all phases of drug development through the Michael Weintraub Pharmaceutical Consulting firm. Using his experience as a former Head of the Office of OTC Drugs for the United States Food and Drug Administration (FDA), Dr. Weintraub specializes in preparing for interactions with the FDA, specifically with Pre-IND, IND end of phase 3, Pre-NDA, and in special meetings. He conducts mock FDA audits and provides guidance for all stages of preparation for Advisory Committee meetings.
Bradford Berk, MD, PhD
Dr. Berk is currently Director of the Rochester Neurorestorative Institute. Dr. Berk is also Distinguished Professor of Medicine, Pathology, and Pharmacology & Physiology at the University of Rochester. He received his M.D. and Ph.D. degrees from the University of Rochester. He has served on the faculties of Harvard Medical School, Emory University, and the University of Washington. Dr. Berk was previously CEO of the University of Rochester Medical Center (2006-2015) as well as Chairman of Medicine (1999-2006) and Chief of the Cardiology Unit (1998-2003) at the University of Rochester. In addition he was Director of the Aab Cardiovascular Research Institute. Dr. Berk is a fellow of the American Heart Association and the American College of Cardiology, and a member of the Association of American Physicians.
Mr. Colpoys is an experienced executive in the biopharma/medtech industry. Since leaving Genentech in 1995, he has been involved in the startup and structuring of more than a dozen companies as either an active member of senior management or in his role as a consultant via his activities as President of Galileo Consulting, Inc. His 30 years of experience across a broad range of operational activities makes him a valued advisor to Efferent Labs. Mr. Colpoys assist's in the formulation of strategy and communication with potential collaborators and licensees.